Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane

Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane

US Patent 10857229 · Granted Dec 8, 2020

Estimated economic value: $457,305,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Treatment of ovarian cancer in patients with ascites using a specific binding ag2024
Treatment of ovarian cancer in patients with ascites using a specific binding ag2024
Detecting immunological changes in HIV infected patient samples1992